CA-SENTRY
Sentry, the leader in developer-first application monitoring, today announced it has acquired Codecov, the leading dedicated code coverage reporting solution, providing developers with actionable insights into their workflow. The acquisition expands Sentry’s product offering for development teams to improve code quality and velocity even earlier in the development life cycle, helping to accelerate remediation and enabling the delivery of better end-user experiences.
“Our mission has always been to empower developers to ship high quality code, faster than anyone else through context and insights, versus dashboards and tools that frankly weren’t built for resolution,” said Milin Desai, CEO of Sentry. “The Codecov team shares this singular focus – and enables us to offer developers even more comprehensive insight into their application’s code quality earlier in the development cycle.”
Codecov is the leading dedicated code coverage solution, which helps thousands of development teams at companies like Lyft, Slack, Washington Post, GoodRx, and Alteryx, confidently ship stable code. Similar to Sentry, Codecov works within developers’ existing workflows for software development, providing feedback, insight, and ownership over the quality of code regardless of platform, language, or CI/CD tooling. With the acquisition, Sentry customers will benefit from insights and protection over their code quality both pre- and post-deployment.
"At Lyft, we want to help our developers reliably ship code as fast as possible by providing an environment that allows them to feel confident to make and ship changes in code," said Jun Li, Staff Software Engineer at Lyft. "Codecov provides a source of truth for our teams. It reduces friction as it is flexible enough to fit into any language and CI/CD so engineers can see the impact and dig deeper into code changes, all in one place. The implementation of Codecov has improved the overall developer experience and we're seeing more and more adoption of it across our teams.”
“From day one, our primary focus has been on using tools like code coverage to help developers ship quickly and reliably,” said Jerrod Engelberg, CEO of Codecov. “There’s an obvious alignment between Sentry and Codecov in how we empower developers to feel confident in making and shipping changes. We are climbing the same summit of software reliability from opposite sides, and with this, our customers new and old will experience faster development cycles, quicker discovery and remediation of bugs, and an overall better developer experience. ”
Codecov providing intelligent code coverage furthers Sentry’s commitment to addressing the evolving needs of software developers who are using tooling that is not purpose-built for their workflows or their most pressing problems. The addition of Codecov, along with Sentry’s other recent investments will serve to evolve application monitoring for software developers everywhere.
Codecov’s talented and experienced team, including co-founders Jerrod Engelberg and Eli Hooten, will join the Sentry team.
Read the Sentry and Codecov blogs to learn more about how the companies will work together to bring a new level of actionable insight directly into the developer’s workflow.
About Sentry
For software teams, Sentry is essential for monitoring application code quality. From Error tracking to Performance monitoring, developers can see clearer, solve quicker, and learn continuously about their applications — from frontend to backend. Loved by more than 3.5 million developers and 85,000 organizations worldwide, Sentry provides code-level observability to many of the world’s best-known companies like Disney, Cloudflare, Eventbrite, Slack, Supercell, and Rockstar Games. Learn more at sentry.io or follow Sentry on GitHub, Twitter, Dribbble, or LinkedIn.
About Codecov
Codecov is the leading dedicated code coverage reporting solution focused on helping developers quickly ship reliable code while helping engineering teams save time and improve the overall developer experience. The company helps thousands of development teams at some of the world’s largest companies like Lyft, Slack, Washington Post, GoodRx, and Alteryx, confidently deliver stable and bug-free code with highly integrated tools to surface coverage insights where they are needed.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221129006193/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom